JIR
EGRX

James Investment Research’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

James Investment Research’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,704
Closed -$48K – 557
2023
Q1 		$48K Buy
+1,704
New +$50.6K 0.01% 368
2017
Q3 		– Sell
-14,470
Closed -$1.14M – 814
2017
Q2 		$1.14M Buy
+14,470
New +$1.18M 0.04% 390

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

James Investment Research's EGRX Position: Q2 2023 in Review

James Investment Research sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 1,704 shares — an estimated $48K sold.

James Investment Research first reported a position in EGRX in Q2 2017 and held it in 2 quarters. The position peaked at $1.14M in Q2 2017. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • James Investment Research reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • James Investment Research sold 1,704 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $48K.
  • James Investment Research first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • James Investment Research's Eagle Pharmaceuticals, Inc. position peaked at $1.14M in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on James Investment Research's 13F filing for Q2 2023, filed 7 Aug 2023.